Is intrathecal anti-CD20 an option to target compartmentalized CNS inflammation in progressive MS?

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 2, 2015, Pages e84-

  Weber, Martin S ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; RITUXIMAB;

B LYMPHOCYTE; CEREBROSPINAL FLUID; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; HUMORAL IMMUNE DEFICIENCY; LYMPHOCYTE SUBPOPULATION; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 85020238932     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000084     Document Type: Editorial

References (11)

1. Hauser SL, Waubant E, Arnold DL, et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358: 676-688.
2. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378:1779-1787.
3. Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014;82:573-581.
4. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010;68:369-383.
5. Molnarfi N, Schulze-Topphoff U, Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013;210:2921-2937.
6. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010;67:452-461.
7. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-1104.
8. Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 2007;7:239-244.
9. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350-1356.
10. Svenningsson A, Bergman J, Dring A, et al. Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol Neuroimmunol Neuroinflamm 2015;2:e79; doi: 10.1212/NXI.0000000000000079.
11. Lehmann-Horn K, Kinzel S, Feldmann L, et al. Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity. Ann Clini Transl Neurol 2014;1: 490-496.